Enliven Therapeutics moves ELVN-001 closer to Phase 3 as CML drug competition intensifies
Find out how Enliven Therapeutics’ ELVN-001 data and FDA alignment could reshape chronic myeloid leukemia drug development.
Why Merck’s Terns acquisition puts chronic myeloid leukemia back in the oncology dealmaking spotlight
Merck needs more than Keytruda. TERN-701 could make chronic myeloid leukemia a sharper test of its next oncology strategy.
Merck’s Terns deal clears antitrust hurdle as TERN-701 becomes bigger oncology test
Merck cleared one deal hurdle. TERN-701 still has to prove whether chronic myeloid leukemia can justify a $6.7 billion bet.